Potentiation of insulin secretion in vitro by serotonin antagonists.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D046508:Culture Techniques; D003533:Cyproheptadine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D010134:Fenclonine / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D006220:Haloperidol / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D008784:Methysergide / Q000494:pharmacology; D010179:Pancreas / Q000187:drug effects*; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D012701:Serotonin / Q000502:physiology; D012702:Serotonin Antagonists; D013268:Stimulation, Chemical; D014044:Tolbutamide / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D007328:Insulin; D012702:Serotonin Antagonists; D010643:Phenoxybenzamine; D003533:Cyproheptadine; D012701:Serotonin; D014044:Tolbutamide; D011433:Propranolol; D005947:Glucose; D006220:Haloperidol; D010134:Fenclonine; D004298:Dopamine; D008784:Methysergide